356 related articles for article (PubMed ID: 32572259)
1. Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors.
Parua PK; Fisher RP
Nat Chem Biol; 2020 Jul; 16(7):716-724. PubMed ID: 32572259
[TBL] [Abstract][Full Text] [Related]
2. Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer.
Goel B; Tripathi N; Bhardwaj N; Jain SK
Curr Top Med Chem; 2020; 20(17):1535-1563. PubMed ID: 32416692
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule degraders of cyclin-dependent kinase protein: a review.
Yu B; Du Z; Zhang Y; Li Z; Bian J
Future Med Chem; 2022 Jan; 14(3):167-185. PubMed ID: 34939427
[TBL] [Abstract][Full Text] [Related]
4. Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery.
Fisher RP
Transcription; 2019 Apr; 10(2):47-56. PubMed ID: 30488763
[TBL] [Abstract][Full Text] [Related]
5. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
Santo L; Siu KT; Raje N
Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
Klein MA
Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
[TBL] [Abstract][Full Text] [Related]
7. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
Abate AA; Pentimalli F; Esposito L; Giordano A
Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of transcriptional cyclin-dependent kinases.
Galbraith MD; Bender H; Espinosa JM
Transcription; 2019 Apr; 10(2):118-136. PubMed ID: 30409083
[TBL] [Abstract][Full Text] [Related]
9. Naturally Sourced CDK Inhibitors and Current Trends in Structure-Based Synthetic Anticancer Drug Design by Crystallography.
Nandi S; Dey R; Dey S; Samadder A; Saxena AK
Anticancer Agents Med Chem; 2022; 22(3):485-498. PubMed ID: 34503422
[TBL] [Abstract][Full Text] [Related]
10. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma.
García-Reyes B; Kretz AL; Ruff JP; von Karstedt S; Hillenbrand A; Knippschild U; Henne-Bruns D; Lemke J
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340359
[TBL] [Abstract][Full Text] [Related]
11. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.
Liao Y; Feng Y; Shen J; Hornicek FJ; Duan Z
Cancer Metastasis Rev; 2016 Jun; 35(2):151-63. PubMed ID: 26669603
[TBL] [Abstract][Full Text] [Related]
12. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).
Sánchez-Martínez C; Lallena MJ; Sanfeliciano SG; de Dios A
Bioorg Med Chem Lett; 2019 Oct; 29(20):126637. PubMed ID: 31477350
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Targeting of the General RNA Polymerase II Transcription Machinery.
Martin RD; Hébert TE; Tanny JC
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397434
[TBL] [Abstract][Full Text] [Related]
14. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
[TBL] [Abstract][Full Text] [Related]
15. CDK regulation of transcription by RNAP II: Not over 'til it's over?
Fisher RP
Transcription; 2017 Mar; 8(2):81-90. PubMed ID: 28005463
[TBL] [Abstract][Full Text] [Related]
16. Novel potent pharmacological cyclin-dependent kinase inhibitors.
Węsierska-Gądek J; Chamrád I; Kryštof V
Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
[TBL] [Abstract][Full Text] [Related]
17. CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets.
Kohlmeyer JL; Gordon DJ; Tanas MR; Monga V; Dodd RD; Quelle DE
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32344731
[TBL] [Abstract][Full Text] [Related]
18. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
[TBL] [Abstract][Full Text] [Related]
19. The history and future of targeting cyclin-dependent kinases in cancer therapy.
Asghar U; Witkiewicz AK; Turner NC; Knudsen ES
Nat Rev Drug Discov; 2015 Feb; 14(2):130-46. PubMed ID: 25633797
[TBL] [Abstract][Full Text] [Related]
20. Pause, play, repeat: CDKs push RNAP II's buttons.
Sansó M; Fisher RP
Transcription; 2013; 4(4):146-52. PubMed ID: 23756342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]